HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Pharmacokinetics of mycophenolic acid after haplo-hematopoietic stem cell transplantation in Japanese recipients

Files in This Item:
Kazuki Uchiyama HUSCAP.pdf379.59 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/81072

Title: Pharmacokinetics of mycophenolic acid after haplo-hematopoietic stem cell transplantation in Japanese recipients
Authors: Uchiyama, Kazuki Browse this author
Saito, Yoshitaka Browse this author →KAKEN DB
Takekuma, Yoh Browse this author →KAKEN DB
Sugita, Junichi Browse this author
Teshima, Takanori Browse this author →KAKEN DB
Sugawara, Mitsuru Browse this author →KAKEN DB
Keywords: Mycophenolate mofetil (MMF)
mycophenolic acid (MPA)
haploidentical hematopoietic stem cell transplantation (haplo-HSCT)
enterohepatic circulation (EHC)
Issue Date: 22-Dec-2020
Publisher: SAGE Publications
Journal Title: Journal of oncology pharmacy practice
Start Page: 1078155220980815
Publisher DOI: 10.1177/1078155220980815
Abstract: Purpose : Mycophenolate mofetil (MMF), a mycophenolic acid (MPA) prodrug, is used to prevent graft-versus-host disease (GVHD) in hematopoietic stem cell transplantation (HSCT). Although previous studies have reported that enterohepatic circulation (EHC) of MPA, which is usually observed in MMF-treated patients, does not occur in HSCT patients, it is unclear what happens in haploidentical-HSCT (haplo-HSCT) patients, who are using post-transplant cyclophosphamide. This study was conducted to investigate MPA pharmacokinetics in haplo-HSCT patients. Methods : Seventeen haplo-HSCT patients, who received MMF for GVHD prophylaxis, were enrolled in this study. We collected blood samples on days 14 and 28, and plasma MPA concentrations were measured by high-performance liquid chromatography; pharmacokinetic parameters such as area under the curve (AUC), mean residence time (MRT), and apparent oral clearance (CL/F) were measured with moment analysis. We also evaluated EHC as AUC(6-12h)/AUC(0-12h.) Results : There was no significant difference in MPA pharmacokinetic parameters between days 14 and 28. There was also no difference between the pharmacokinetic parameter changes and diarrhea. Additionally, varying plasma MPA concentrations suggested that MPA EHC did not occur. Conclusion : In this study, we revealed the pharmacokinetics of MMF in Japanese haplo-HSCT recipients. Additionally, our study demonstrated that MPA EHC might not occur in Japanese haplo-HSCT recipients.
Rights: Kazuki Uchiyama, Yoshitaka Saito, Yoh Takekuma, Junichi Sugita, Takanori Teshima, Mitsuru Sugawara, Pharmacokinetics of mycophenolic acid after haplo-hematopoietic stem cell transplantation in Japanese recipients, Journal of Oncology Pharmacy Practice (OnlineFirst), Copyright © 2020., DOI:10.1177/1078155220980815.
Type: article (author version)
URI: http://hdl.handle.net/2115/81072
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 内山 数貴

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 

 - Hokkaido University